LEGN

Legend Biotech Corporation ADR (LEGN) | Rumor.io

Legend Biotech

LEGN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,093

Bullish sentiment (50-day avg)79%

Price to earnings ratio-11.5

Market capitalization3.6B

Earnings per share-0.5

Dividend yield (TTM)—

Revenue (annual)1B

Net income (annual)-296.8M

Social

What share of all stock conversation is about LEGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% +0

Sep 16

Legend Biotech Corporation ($LEGN) has been trading at its cheapest levels since 2020, despite significant progress in sales and pipelines.
The company has named Ingrid Zhang, a former Chief Commercial Officer for Novartis International, as its new CEO, which may be a catalyst for a potential partnership or collaboration with Novartis.
The appointment of Ingrid Zhang and the upcoming in-vivo data from Legend Biotech's IND (Investigational New Drug) filing may lead to a partnership or collaboration with Novartis, given the company's internal cell therapy pipeline vulnerabilities.

Generated by AI

Sentiment

Of the messages about LEGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% +12.96	83.92% +5.46	84.3% -10.24
Bearish	0% 0	0% -12.96	16.08% -5.46	15.7% +10.24

Bullish· Aug 11

The company has reported its first profitable quarter, with a net income of $33.2M, a significant improvement from a $125.4M loss in the same period last year.
CARVYKTI sales have seen a 50% year-over-year growth to $657M, driving a 52% increase in total revenue to $387.5M.
The company's CARVYKTI therapy has demonstrated a 100% overall response rate (ORR) in the higher-dose LB2501 cohort, highlighting its potential as a commercial cash cow.

Bearish· Jul 27

The sudden CEO departure from Legend Biotech Corporation ($LEGN) triggered market turmoil and prompted investors to reassess the growth logic of CAR-T therapy.
The CEO's resignation was not due to any kind of fraud, but the lack of transparency surrounding the departure may have contributed to the sharp drop in the company's stock price.
The CEO's departure may have been driven by the company's slowing CAR-T growth, which has been threatened by emerging off-the-shelf products in multiple myeloma.

Generated by AI

Topics

Of the messages about LEGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	83.33%	85.93%	67.09%
Technical Analysis	—	16.67%	5.19%	7.77%
Analysts	—	0%	8.89%	6.45%
Earnings	—	0%	0%	13.47%
Controversies	—	0%	0%	0.99%
Macro	—	0%	0%	4.24%

Jun 2

Legend Biotech's in vivo CAR-T therapy LB2501 shows remarkable Phase 1 results in relapsed/refractory B-cell lymphoma, with a 100% Objective Response Rate and 83% Complete Response Rate.
Legend Biotech announces late-breaking oral presentation at EHA 2026 showcasing initial Phase 1 in vivo CAR-T data with LB2501 in non-Hodgkin lymphoma, with promising results for a potential first-in-class CD19/CD20 dual-targeting in vivo CAR-T therapy.
Legend Biotech reports strong preliminary Phase 1 clinical data for its novel in vivo CAR-T therapy LB2501, showing high response rates and a favorable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Generated by AI

Community

Of the messages about LEGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	60%	57.89%	65.09%	43.47%
Newcomers	40%	42.11%	34.91%	56.53%

Regulars· Sep 16

$LEGN is trading at its cheapest levels since 2020, despite progress in sales and pipelines, making it a good time to buy.
The selloff in $LEGN may be due to a lack of understanding of the company's commercial success, pipeline, and cash position, which are not being reflected in the stock price.
The chances of a Novartis-Legend transaction or formal collaboration are high, with a 40-55% chance if the durability data is positive, and a 20-30% chance if it is merely acceptable.

Newcomers· Aug 18

Many newcomers are discussing Legend Biotech Corporation ($LEGN) as a potential buyout candidate, citing its low valuation and strong fundamentals.
Some newcomers are analyzing the company's CAR-T therapy pipeline, highlighting the success of its Phase 1 trial and the potential for a breakthrough in multiple myeloma treatment.
Others are pointing out the disconnect between $LEGN's strong commercial performance and its low stock price, suggesting that institutional accumulation is underway, potentially setting the stage for a buyout or valuation re-rate.

Generated by AI

Legend Biotech (NASDAQ:LEGN) presents a compelling equity thesis centered on transforming breakthrough oncology innovation into a high-margin, cash-generative cell therapy franchise. Maintaining a fortress balance sheet anchored by approximately $965 million in cash, cash equivalents, and time deposits as of June 30, fortified by $212 million in net proceeds from a public offering of American […]

5d agoYahoo Finance

Also Discussed

Investors talking about LEGN also mention

#	Name	Attention
1	Alector Inc.ALEC	0%new
2	ACLX - Arcellx, Inc.	——
3	Nuvalent, Inc.NUVL	0%0
4	Genmab A/S American Depositary SharesGMAB	0%0
5	Mineralys Therapeutics, Inc.MLYS	0%+0
6	TSVT - 2seventy bio, Inc.	——
7	GRCL - Gracell Biotechnologies Inc.	——
8	IDEAYA Biosciences Inc.IDYA	0%-0.01
9	Vera Therapeutics Inc.VERA	0%new
10	Immunocore Holdings plc ADRIMCR	0%0

Legend Biotech Corporation ADR

Healthcare
Biotechnology

Legend Biotech Corporation ADR is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing cell therapies for oncology and other serious diseases. The company’s work centers on advanced immunotherapy platforms, including chimeric antigen receptor T-cell approaches and other cellular therapies designed to target hard-to-treat cancers. Its portfolio is led by CARVYKTI, a BCMA-directed CAR-T therapy used in multiple myeloma, and it also supports additional investigational cell therapy programs across hematologic and solid tumor settings. Legend Biotech serves patients and healthcare providers through a global footprint spanning the United States, China, and Europe, combining research, manufacturing, and commercialization capabilities within a single operational model. As an ADR, Legend Biotech Corporation ADR provides market access to a company positioned at the intersection of biotechnology innovation and specialty cancer treatment.

Website

Location

2101 Cottontail Lane

Somerset, NJ, 08873

United States

Social

What share of all stock conversation is about LEGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% 0	0% +0

Sep 16

Legend Biotech Corporation ($LEGN) has been trading at its cheapest levels since 2020, despite significant progress in sales and pipelines.
The company has named Ingrid Zhang, a former Chief Commercial Officer for Novartis International, as its new CEO, which may be a catalyst for a potential partnership or collaboration with Novartis.
The appointment of Ingrid Zhang and the upcoming in-vivo data from Legend Biotech's IND (Investigational New Drug) filing may lead to a partnership or collaboration with Novartis, given the company's internal cell therapy pipeline vulnerabilities.

Generated by AI

Sentiment

Of the messages about LEGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% +12.96	83.92% +5.46	84.3% -10.24
Bearish	0% 0	0% -12.96	16.08% -5.46	15.7% +10.24

Bullish· Aug 11

The company has reported its first profitable quarter, with a net income of $33.2M, a significant improvement from a $125.4M loss in the same period last year.
CARVYKTI sales have seen a 50% year-over-year growth to $657M, driving a 52% increase in total revenue to $387.5M.
The company's CARVYKTI therapy has demonstrated a 100% overall response rate (ORR) in the higher-dose LB2501 cohort, highlighting its potential as a commercial cash cow.

Bearish· Jul 27

The sudden CEO departure from Legend Biotech Corporation ($LEGN) triggered market turmoil and prompted investors to reassess the growth logic of CAR-T therapy.
The CEO's resignation was not due to any kind of fraud, but the lack of transparency surrounding the departure may have contributed to the sharp drop in the company's stock price.
The CEO's departure may have been driven by the company's slowing CAR-T growth, which has been threatened by emerging off-the-shelf products in multiple myeloma.

Generated by AI

Topics

Of the messages about LEGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	83.33%	85.93%	67.09%
Technical Analysis	—	16.67%	5.19%	7.77%
Analysts	—	0%	8.89%	6.45%
Earnings	—	0%	0%	13.47%
Controversies	—	0%	0%	0.99%
Macro	—	0%	0%	4.24%

Jun 2

Legend Biotech's in vivo CAR-T therapy LB2501 shows remarkable Phase 1 results in relapsed/refractory B-cell lymphoma, with a 100% Objective Response Rate and 83% Complete Response Rate.
Legend Biotech announces late-breaking oral presentation at EHA 2026 showcasing initial Phase 1 in vivo CAR-T data with LB2501 in non-Hodgkin lymphoma, with promising results for a potential first-in-class CD19/CD20 dual-targeting in vivo CAR-T therapy.
Legend Biotech reports strong preliminary Phase 1 clinical data for its novel in vivo CAR-T therapy LB2501, showing high response rates and a favorable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Generated by AI

Community

Of the messages about LEGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	60%	57.89%	65.09%	43.47%
Newcomers	40%	42.11%	34.91%	56.53%

Regulars· Sep 16

$LEGN is trading at its cheapest levels since 2020, despite progress in sales and pipelines, making it a good time to buy.
The selloff in $LEGN may be due to a lack of understanding of the company's commercial success, pipeline, and cash position, which are not being reflected in the stock price.
The chances of a Novartis-Legend transaction or formal collaboration are high, with a 40-55% chance if the durability data is positive, and a 20-30% chance if it is merely acceptable.

Newcomers· Aug 18

Many newcomers are discussing Legend Biotech Corporation ($LEGN) as a potential buyout candidate, citing its low valuation and strong fundamentals.
Some newcomers are analyzing the company's CAR-T therapy pipeline, highlighting the success of its Phase 1 trial and the potential for a breakthrough in multiple myeloma treatment.
Others are pointing out the disconnect between $LEGN's strong commercial performance and its low stock price, suggesting that institutional accumulation is underway, potentially setting the stage for a buyout or valuation re-rate.

Generated by AI

Legend Biotech

Social

Sep 16

Sentiment

Bullish· Aug 11

Bearish· Jul 27

Topics

Jun 2

Community

Regulars· Sep 16

Newcomers· Aug 18

News

H.C. Wainwright reiterates Legend Biotech stock rating on durability data

Legend Biotech reports 5-year CARVYKTI data in myeloma patients

Can Legend Biotech (LEGN) Turn Cell Therapy Scale Into Compounding Wealth?

Legend Biotech CFO Carlos Santos sells $49,630 in shares

Legend Biotech taps Novartis veteran Zhang as CEO

Legend Names Novartis Executive as CEO

Also Discussed

Legend Biotech Corporation ADR

Company Information

Location

News

H.C. Wainwright reiterates Legend Biotech stock rating on durability data

Legend Biotech reports 5-year CARVYKTI data in myeloma patients

Can Legend Biotech (LEGN) Turn Cell Therapy Scale Into Compounding Wealth?

Legend Biotech CFO Carlos Santos sells $49,630 in shares

Legend Biotech taps Novartis veteran Zhang as CEO

Legend Names Novartis Executive as CEO

Also Discussed

Social

Sep 16

Sentiment

Bullish· Aug 11

Bearish· Jul 27

Topics

Jun 2

Community

Regulars· Sep 16

Newcomers· Aug 18